| Document |
Document Title |
|
WO/2014/125075A1 |
The present invention relates to a antibiotically active compounds characterized by general formula (I), wherein X1, BB, BC, BD, BE and X2 are building blocks with D1, D2, D3, D4 or D5 being linkers which comprise carbon, sulphur, nitrog...
|
|
WO/2014/121884A1 |
The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states...
|
|
WO/2014/118361A1 |
The invention relates to compounds and pharmaceutical compositions useful in combination with tetracyclines in the treatment of bacterial infections caused by Gram- positive and Gram-negative pathogens, with particular efficacy in tetrac...
|
|
WO/2014/115638A1 |
This method for manufacturing 3,5-dimethyl-1-adamantanamine includes the following steps (i) through (iii). (i) A step for reacting 3,5-dimethyl-1-adamantanol with oxygen and nitrile in an organic solvent to obtain a reaction solution. (...
|
|
WO/2014/111720A1 |
The present invention relates to a compound of formula (I) in crystalline form, wherein said compound is in the form of the free base or a pharmaceutically acceptable salt thereof, or a solvate of the free base or salt form thereof.The i...
|
|
WO/2014/111949A1 |
The present invention relates to a simple and commercially feasible preparation of Fingolimod hydrochloride with high purity of greater than 99.9%. The.present invention also provides novel intermediates for the preparation of Fingolimod...
|
|
WO/2014/110036A1 |
Compounds of formula (I): [Formula should be inserted here]; where [Formula should be inserted here], n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed co...
|
|
WO/2014/108564A1 |
The subject matter of the present invention is the novel molecules of formulae E, E' and F. These molecules prove to be synthesis intermediates that are very advantageous for the manufacture of derivatives of sphingosine or of ceramides ...
|
|
WO/2014/104272A1 |
The present invention provides a cinnamic acid amide derivative having an excellent analgesic activity. The cinnamic acid amide derivative according to the present invention is a compound that exhibits an excellent analgesic activity on ...
|
|
WO/2014/104015A1 |
A diamine represented by formula (1). (In the formula, A represents an organic group that can be eliminated by heat. B represents -CH2-, -O-, -S-, or -NH-. X represents a single bond or a divalent organic group. Y represents a single bon...
|
|
WO/2014/105379A1 |
A composition is provided comprising dispersed particles in an aqueous medium, wherein said dispersed particles comprise fatty amide and one or more fatty acid, wherein 50 mole% or more of said fatty acid in is the carboxylate form, and ...
|
|
WO/2014/096373A1 |
The present invention refers to solid forms of agomelatine, a process for their preparation and pharmaceutical compositions containing them. The present invention also relates to a process for the manufacture of N-[2-(7-methoxy- -naphtha...
|
|
WO/2014/096375A1 |
The present invention relates to a process for preparing chiral γ-aryl-β-aminobutyric acid compounds and derivatives thereof.
|
|
WO/2014/100833A1 |
Benzamide compounds and derivatives thereof, as can be used for selective inhibition of the SIRT2 enzyme and/or therapeutic use in the treatment of Huntington's disease.
|
|
WO/2014/090731A1 |
The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric m...
|
|
WO/2014/093252A1 |
The present disclosure provides antimicrobial compounds, compositions comprising such antimicrobial compounds, and methods of their use, in particular, antibacterial compounds and antifungal compounds. In certain aspects, the antimicrobi...
|
|
WO/2014/084743A1 |
The invention relates to compounds that are useful for the preparation of dendrimer compounds, the use of these compounds for preparing dendrimers and processes for preparing the compounds.
|
|
WO/2014/084676A1 |
The present invention provides: a novel pseudoceramide compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof or a solvate thereof. The present invention has a skin protecting effect...
|
|
WO/2014/083202A1 |
The invention relates to the use of cinnamic acid derivatives of formula (I), in which R1, R2, R3 and R4 represent, independently from each other, hydrogen or a methoxy group, as flavouring agents.
|
|
WO/2014/084471A1 |
The present invention relates to an antimalarial composition containing an N-acetyl-L-Leucyl-L-leucyl-L-norleucinal (ALLN) derivative compound as an active ingredient. The ALLN derivative compound of the present invention can be used as ...
|
|
WO/2014/075691A1 |
Disclosed herein are oxiran amines useful for the treatment of a variety of diseases. The oxiran amines are useful in the manufacture of pharmaceutical compositions. The pharmaceutical composition may be used for the treatment or prevent...
|
|
WO/2014/075676A1 |
Disclosed herein are amines useful for the treatment of a variety of diseases. The amines are useful in the manufacture of pharmaceutical compositions. The pharmaceutical composition may be used for the treatment or prevention of a disea...
|
|
WO/2014/073994A2 |
The invention presents new alkanolamide derivatives of cinnamic acid of general Formula 1 and the use of alkanolamide derivatives of cinnamic acid for production of drugs for neurological disorders like epilepsy and/or pain.
|
|
WO/2014/074734A1 |
Here provided is a method for regulating retinal endothelial cell viability in a mammal by administering to the mammal a therapeutically effective amount of a quinic acid analog. The method may be applied to prevent, treat or cure pathol...
|
|
WO/2014/069875A2 |
The present invention relates to a novel method for preparing acetaminophen, and more specifically, to a method for preparing acetaminophen, comprising the steps of: reacting a benzene compound substituted with a specific functional grou...
|
|
WO/2014/070983A1 |
The invention relates to plasminogen activator- 1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The invention includes, but is not limited to, the use of such com...
|
|
WO/2014/066361A1 |
The composition of the present invention related to a quaternary ammonium salt detergent and the use of such quaternary ammonium salt detergents in a fuel composition to reduce diesel injector deposits and remove or clean up existing dep...
|
|
WO/2014/066344A1 |
The composition of the present invention related to a quaternary ammonium salt detergent and the use of such quaternary ammonium salt detergents in a fuel composition to reduce diesel injector deposits and remove or clean up existing dep...
|
|
WO/2014/064706A1 |
Provided herein are novel, commercially viable and industrially advantageous processes for the preparation of Agomelatine or a salt thereof, in high yield and purity, using novel intermediates.
|
|
WO/2014/059516A1 |
A process for preparing an acrylamide-based crosslinking monomer comprising reacting in the presence of a catalyst an isocyanate compound containing at least two isocyanate groups with one of acrylic acid or methacrylic acid. These acryl...
|
|
WO/2014/061470A1 |
Provided are: a method for producing an N,N-dialkylhomofarnesic acid amide, which is a precursor of (±)-3a,6,6,9a-tetramethyldodecahydronaphtho[2,1-b]furan that is useful as a fragrance, with a high raw material recovery ratio, high pur...
|
|
WO/2014/060852A2 |
Compounds that are useful in the synthesis of 2-amino-4,6-dimethoxybenzamide derivatives and other benzamide compounds.
|
|
WO/2014/061467A1 |
Provided is a liquid composition having low environmental impact, and having the property of thickening or gelling through the application of strain. This liquid composition contains the following components (A), (B), (C), and (D). Compo...
|
|
WO/2014/061034A1 |
THE PRESENT INVENTION RELATES TO AN IMPROVED PROCESS FOR THE PREPARATION OF (1R,5S)-N-[3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL]-3-[
2(S)-[[[(1,1-DIMETHYLETHYL)AMINO]CARBONYL] AMINO]-3,3-DIMETHYL-1-OXOBUTYL]-6,6-DIMETHYL-3-AZABICYCLO...
|
|
WO/2014/057078A1 |
The present application relates to compounds of formula (I), wherein R1 to R5 are as defined in claim 1, a pharmaceutical composition thereof and said compounds for use in the treatment of diseases related with the activity of P2X7 recep...
|
|
WO/2014/056421A1 |
Provided are a 1-cyan-1-(7-methoxyl-1-naphtyl) methanol ester compound, and preparation method and use thereof in the preparation of agomelatine intermediate 2-(7-methoxyl-1-naphtyl) ethylamine. Also provided is an agomelatine preparatio...
|
|
WO/2014/056939A1 |
The present invention relates to novel compounds, particularly for use as additives in a lipidic cubic phase material, and to novel lipidic cubic phase materials. These materials are biocompatible, stable and transparent and can encapsul...
|
|
WO/2014/051971A1 |
A multistage process for the preparation of methacrylic acid and esters thereof via the hydrolysis of ACH, cracking the hydrolysis products, and converting the cracked products to the desired acid or ester, wherein the average temperatur...
|
|
WO/2014/048165A1 |
Disclosed is a compound as a potassium channel modulator, which is a compound of general formula (I) or a pharmaceutically acceptable salt thereof. Such compound can be used to prepare drugs for increasing the flow of ions in potassium c...
|
|
WO/2014/050426A1 |
The present invention provides a method for producing a liquid crystal composition in a single step, said liquid crystal composition using two or more different types of carboxylic acid as a type of raw material, and having the ability t...
|
|
WO/2014/044873A1 |
There are provided amino acid derivatives of formula V and VI as defined herein which are pyrrolysine analogs for use in bioconjugation processes.
|
|
WO/2014/041125A1 |
The present invention relates to novel inhibitors of p21. These inhibitors are useful as therapeutic agents for promoting cell regeneration and in the treatment of cancer. Improvement of cell regeneration is particularly desirable in pat...
|
|
WO/2014/037308A1 |
Disclosed is a method for the synthesis of N-H or N-alkyl 2-propynamides useful as intermediate in the manufacture of pharmaceutically active ingredients.
|
|
WO/2014/039917A1 |
Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases o...
|
|
WO/2014/034124A1 |
Provided is a chemical reaction which omits or simplifies treatment after reaction. This problem is solved by a method for producing a product by a chemical reaction which comprises: (A) a step of producing a product by reacting a substa...
|
|
WO/2014/030038A1 |
A process of producing N-acyl amino acid based surfactants of Formula (I), wherein, R is selected from C6 to C22 alkyl group, R1 is selected from H, C1 to C4 alkyl, R2 is selected from all groups on a carbon of natural amino acids, R3 is...
|
|
WO/2014/031012A1 |
The invention relates to compounds of use as targeted cytotoxic agents and methods of use thereof. In particular, the invention relates to prodrugs that are substantially resistant to human AKR1C3 enzyme metabolism, methods of cell ablat...
|
|
WO/2014/022879A1 |
The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoactonitrile derivatives (AADs) in the treatment...
|
|
WO/2014/019995A1 |
The present invention relates to a novel process for preparing substituted biphenyls of the formula (III) by reacting arenes of the formula (I) with arenes of the formula (11) in the presence of a transition metal catalyst, and of at lea...
|
|
WO/2014/020071A1 |
Compound of formula [C+] [A-], wherein R1, R2, R3, R4 are independently –H; –C1 to –C12 -alkyl or alkenyl; –OH; –SH; –CN; –F; –Cl; –Br; –I; R5 is –H, –C1 to –C12 –alkyl or alkenyl R6 is –C1 to –C12 –alky...
|
